摘要
幽门螺杆菌(Helicobacter pylori)是一种人体常见的致病菌,益生菌及其产物已经被认为具有缓解H.pylori感染的作用,该研究旨在评价卷曲乳杆菌CCFM1118制备的后生元1118-Inactivated Bacteria(CCFM1118-IB)对H.pylori感染的缓解作用。该研究通过抑菌实验、细胞黏附实验及菌株共聚集实验分析了CCFM1118-IB对H.pylori生长、定殖的影响;同时使用CCFM1118-IB治疗55名H.pylori感染者,并通过测定感染者^(13)C-尿素呼气值、血清胃蛋白酶原(pepsinogen,PG)浓度、血清生化指标及肠道菌群的组成和丰度等指标以分析CCFM1118-IB对H.pylori感染的缓解作用。实验结果表明,CCFM1118-IB可产生(12.25±0.29)mm的抑菌圈,且对H.pylori具有共聚集作用。同时临床测评显示,CCFM1118-IB可显著降低患者的^(13)C-尿素呼气值、抑制患者PGⅠ/PⅡ升高,并影响患者拟杆菌属、瘤胃球菌等肠道菌的丰度,但CCFM1118-IB并不会影响受试者的正常生理状态。该研究表明,CCFM1118-IB具有抗H.pylori的特性并可以减少H.pylori感染对人类健康的有害影响。
Helicobacter pylori(H.pylori)is a common pathogenic bacterium in humans,which is widely spread in the world.It is a pathogen with potential health hazards associated with a variety of diseases,especially digestive diseases such as chronic gastritis and stomach cancer.Antibiotics are commonly used to treat H.pylori infection,but this has many side effects.In recent years,probiotics and their products have been used for the treatment of H.pylori infection due to their safety,low side effects,and effective elimination.This study aimed to evaluate the alleviating effect of postbiotic element CCFM1118-Inactivated Bacteria(CCFM1118-IB)prepared from Lactobacillus crispatus CCFM1118 on H.pylori infection.The effect of CCFM1118-IB on H.pylori growth and colonization was evaluated using the antibacterial experiment,cell adhesion assay,and strain coaggregation assay.Meanwhile,55 patients with H.pylori infection were treated with CCFM1118-IB at a dose of 2 g twice daily for one month.^(13)C-urea breath test,serum biochemical parameters,serum pepsinogen concentrations,serum cytokine concentrations,and the gut microbiota of patients were measured at baseline and end-of-trial to analyze the effect of CCFM1118-IB in eradicating H.pylori infection in patients.In vitro study results showed that CCFM1118-IB formed an inhibition circle with(12.25±0.29)mm and had a co-aggregating effect with H.pylori,but it was unable to inhibit the adhesion of H.pylori to cells.In the clinical trial,CCFM1118-IB significantly reduced the^(13)C-Urea breath test value,inhibited the elevation of PGⅠ/PGⅡ,and affected the abundance of gut microbiota such as Bacteroides and Ruminococcus in patients.Further analysis found that the regulation of the gut microbiota by CCFM1118-IB may promote the production of beneficial active metabolites,thereby improving the health of the host.However,CCFM1118-IB did not significantly affect the general serum biochemistry and other indicators,indicating that it does not affect the normal physiological status of the subjects.The results demonstrated that CCFM1118-IB has anti-H.pylori properties and diminish the harmful effects of H.pylori infection on human health.
作者
陈峰
李敏玉
刘玲
于雷雷
耿芊
田丰伟
翟齐啸
CHEN Feng;LI Minyu;LIU Ling;YU Leilei;GENG Qian;TIAN Fengwei;ZHAI Qixiao(School of Food Science and Technology,Jiangnan University,Wuxi 214122,China;The First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)
出处
《食品与发酵工业》
CAS
CSCD
北大核心
2024年第9期1-8,共8页
Food and Fermentation Industries
基金
江苏省自然科学基金优秀青年基金项目(BK20220155)
江苏省重点研发计划(社会发展)项目(BE2021623)。
关键词
益生菌
卷曲乳杆菌
后生元
幽门螺杆菌
临床试验
probiotics
Lactobacillus crispatus
postbiotics
Helicobacter pylori
clinical trial
